GlassScriptPhysician profile
Benjamin D Nicholas
NPI 1336631381
$2,773.24
in general payments reported to CMS, 2019-2025
17 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2021: $103 · 2022: $260 · 2023: $507 · 2024: $690 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $988.15 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $376.56 | 2021-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Abbvie INC. | $361.86 | 2022-2023 | |
| Allergan, INC. | $229.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $225.87 | 2022-2025 | Eylea Hd, Eylea |
| Tarsus Pharmaceuticals, INC. | $115.01 | 2024-2025 | Xdemvy |
| Omeros Corporation | $113.10 | 2019-2021 | |
| Alimera Sciences, INC. | $105.52 | 2019 | |
| Oyster Point Pharma, INC. | $60.13 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.57 | 2021 | |
| Glaukos Corporation | $33.47 | 2023 | |
| Dompe US, INC. | $25.40 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $21.05 | 2024 | |
| Apellis Pharmaceuticals, INC. | $19.38 | 2023 | Syfovre |
| Thea Pharma INC. | $17.76 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $17.33 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $13.86 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Nicholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.